NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Shareholders Equity (Quarterly): 148.64M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 148.64M |
| September 30, 2023 | 169.80M |
| June 30, 2023 | 192.12M |
| March 31, 2023 | 220.93M |
| December 31, 2022 | 259.56M |
| September 30, 2022 | 285.89M |
| June 30, 2022 | 292.08M |
| March 31, 2022 | 311.14M |
| December 31, 2021 | 335.65M |
| September 30, 2021 | 354.04M |
| June 30, 2021 | 373.08M |
| March 31, 2021 | 399.58M |
| Date | Value |
|---|---|
| December 31, 2020 | 280.04M |
| September 30, 2020 | 276.70M |
| June 30, 2020 | 301.16M |
| March 31, 2020 | 318.97M |
| December 31, 2019 | 330.72M |
| September 30, 2019 | 339.19M |
| June 30, 2019 | 346.13M |
| March 31, 2019 | -119.18M |
| December 31, 2018 | -108.20M |
| June 30, 2018 | -123.45M |
| December 31, 2017 | -120.98M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
148.64M
Minimum
Dec 2023
399.58M
Maximum
Mar 2021
291.34M
Average
301.16M
Median
Jun 2020
Shareholders Equity (Quarterly) Benchmarks
| Catalent Inc | 3.611B |
| AIM ImmunoTech Inc | 4.826M |
| Perspective Therapeutics Inc | 229.89M |
| Protalix BioTherapeutics Inc | 29.79M |
| Armata Pharmaceuticals Inc | -56.51M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 168.87M |
| Total Liabilities (Quarterly) | 20.23M |
| Current Ratio | 7.791 |